Glenmark Pharmaceuticals Limited on May 29, 2026 reported consolidated net profit of Rs 30.13 crore for the quarter ended March 31, 2026. The company's board also recommended a final dividend of 250% for FY 2025-26.
Consolidated revenue from operations for Q4 FY26 stood at Rs 377.06 crore, compared to Rs 325.62 crore in the same quarter of the previous fiscal year. Net sales for the quarter were Rs 376.03 crore. Total income for the quarter was Rs 395.97 crore.
For the full year FY26, consolidated net profit was Rs 136.20 crore on revenue from operations of Rs 1,698.25 crore. Net sales for FY26 were Rs 1,671.14 crore, up from Rs 1,314.58 crore in FY25. Total expenses for FY26 were Rs 1,319.23 crore.
On a standalone basis, the company reported a net loss of Rs 7.39 crore for Q4 FY26 on revenue from operations of Rs 214.66 crore. Full year standalone net loss was Rs 20.08 crore on revenue from operations of Rs 844.01 crore.
The board recommended a final dividend of Rs 2.50 per share (face value of Re 1 each), representing 250% for FY26. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Consolidated basic EPS for Q4 FY26 was Rs 10.68, while diluted EPS was Rs 10.68. For FY26, consolidated basic EPS was Rs 48.26 and diluted EPS was Rs 48.24.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.